A Phase 2 Multi-Ascending Dose Trial to Assess the Efficacy, Tolerability and Pharmacokinetic Profile of Exendin (9-39) in Patients With Post-bariatric Hyperinsulinemic Hypoglycemia

Trial Profile

A Phase 2 Multi-Ascending Dose Trial to Assess the Efficacy, Tolerability and Pharmacokinetic Profile of Exendin (9-39) in Patients With Post-bariatric Hyperinsulinemic Hypoglycemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Exendin 9 (Primary)
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 12 Jun 2017 According to an Eiger BioPharmaceuticals media release, results (n=19) from this trial were presented at the 2017 American Diabetes Association meeting.
    • 12 Jun 2017 Results published in an Eiger BioPharmaceuticals Media Release
    • 06 Jun 2017 Status changed from recruiting to active, no longer recruiting, according to an Eiger BioPharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top